rolipram has been researched along with Colitis in 3 studies
Colitis: Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Colitis was quantified by a clinical activity score assessing weight loss, stool consistency, and rectal bleeding (range from 0 to 4); by colon length; by a semiquantitative histologic score (range from 0 to 6); and by detecting TNF concentration in colonic tissue by enzyme-linked immunosorbent assay." | 5.31 | Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice. ( Albrich, S; Bidlingmaier, C; Eigler, A; Endres, S; Hartmann, G; Lehr, HA; Schulze, J; Siegmund, B; Tschoep, K, 2000) |
| " We compared the effect of rolipram, a selective PDE4 inhibitor, with steroids on the clinical course of experimental colitis induced by 2,4,6-trinitrobenzenesulfonic acid (TNBS)." | 3.73 | Selective inhibition of phosphodiesterase-4 ameliorates chronic colitis and prevents intestinal fibrosis. ( Guarner, F; Malagelada, JR; Medina, C; Mourelle, M; Salas, A; Videla, S; Vilaseca, J, 2006) |
| " Here we assessed the ability of PDE inhibitors to modulate colitis by exposing mice to 4% (w/v) dextran sulfate sodium (DSS) drinking water for 5 days with or without rolipram, an inhibitor of PDE type 4, or the nonselective PDE inhibitor, pentoxifylline (both at 5 mg/kg, i." | 3.70 | Dextran sulfate sodium-induced colonic histopathology, but not altered epithelial ion transport, is reduced by inhibition of phosphodiesterase activity. ( Diaz-Granados, N; Howe, K; Lu, J; McKay, DM, 2000) |
| "Colitis was quantified by a clinical activity score assessing weight loss, stool consistency, and rectal bleeding (range from 0 to 4); by colon length; by a semiquantitative histologic score (range from 0 to 6); and by detecting TNF concentration in colonic tissue by enzyme-linked immunosorbent assay." | 1.31 | Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice. ( Albrich, S; Bidlingmaier, C; Eigler, A; Endres, S; Hartmann, G; Lehr, HA; Schulze, J; Siegmund, B; Tschoep, K, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Videla, S | 1 |
| Vilaseca, J | 1 |
| Medina, C | 1 |
| Mourelle, M | 1 |
| Guarner, F | 1 |
| Salas, A | 1 |
| Malagelada, JR | 1 |
| Hartmann, G | 1 |
| Bidlingmaier, C | 1 |
| Siegmund, B | 1 |
| Albrich, S | 1 |
| Schulze, J | 1 |
| Tschoep, K | 1 |
| Eigler, A | 1 |
| Lehr, HA | 1 |
| Endres, S | 1 |
| Diaz-Granados, N | 1 |
| Howe, K | 1 |
| Lu, J | 1 |
| McKay, DM | 1 |
3 other studies available for rolipram and Colitis
| Article | Year |
|---|---|
Selective inhibition of phosphodiesterase-4 ameliorates chronic colitis and prevents intestinal fibrosis.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Chronic Disease; Colitis; Colon; Cyclic Nucleotide Pho | 2006 |
Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice.
Topics: Animals; Body Weight; Colitis; Dextran Sulfate; Feces; Female; Hemorrhage; In Vitro Techniques; Mice | 2000 |
Dextran sulfate sodium-induced colonic histopathology, but not altered epithelial ion transport, is reduced by inhibition of phosphodiesterase activity.
Topics: Animals; Biological Transport; Colitis; Colon; Cytokines; Dextran Sulfate; Epithelium; Intestinal Mu | 2000 |